Replagal er indiceret til langtids- enzym- substitutionsterapi i patienter med en bekræftet diagnose af Fabrys sygdom (α- galactosidase A- deficiens).
Replagal is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease (α -galactosidase A deficiency).